M. Weise, M. Bielsky, D. Smet, K. Ehmann, F. Ekman et al., Biosimilars: what clinicians should know, Blood, vol.120, pp.5111-5118, 2012.

E. Van-overbeeke, D. Beleyr, B. De-hoon, J. Westhovens, R. Huys et al., Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists, BioDrugs, vol.31, pp.447-59, 2017.

, Open Medic : base complète sur les dépenses de médicaments interrégimes, 2018.

L. Gulácsi, V. Brodszky, P. Baji, H. Kim, S. Y. Kim et al., Biosimilars for the management of rheumatoid arthritis: economic considerations, Expert Rev Clin Immunol, vol.11, pp.43-52, 2015.

M. I. Aladul, R. W. Fitzpatrick, and S. R. Chapman, Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK, BioDrugs Clin Immunother Biopharm Gene Ther, vol.31, pp.533-577, 2017.

H. P. Cohen, A. Blauvelt, R. M. Rifkin, S. Danese, S. B. Gokhale et al., Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes, Drugs, vol.78, pp.463-78, 2018.

K. K. Jørgensen, I. C. Olsen, G. L. Goll, M. Lorentzen, N. Bolstad et al., Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, doubleblind, non-inferiority trial, The Lancet, vol.389, issue.17, pp.30068-30073, 2017.

C. Jacomet, C. Allavena, F. Peyrol, B. Pereira, L. M. Joubert et al., Perception of antiretroviral generic medicines: one-day survey of HIV-infected patients and their physicians in France, PloS One, vol.10, p.117214, 2015.

J. Wémeau and M. Ladsous,

, Presse Medicale Paris Fr, vol.46, pp.887-896, 1983.

, World Health Organization. GUIDELINES ON EVALUATION OF SIMILAR BIOTHERAPEUTIC PRODUCTS

C. Chapelon-abric, Les biosimilaires en Médecine Interne : bien les connaître pour bien les prescrire. Rev Médecine Interne, 2018.

B. Vezér, Z. Buzás, M. Sebeszta, and Z. Zrubka, Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents, Curr Med Res Opin, vol.32, pp.829-863, 2016.

G. Girolomoni, S. R. Feldman, P. Emery, J. Ghil, J. W. Keum et al., Comparison of injection site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a Phase III study, Br J Dermatol, 2017.

F. Cantini and M. Benucci, Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?, Ann Rheum Dis, vol.2017

M. Scherlinger, T. Schaeverbeke, and . Response, Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Cantini and Benucci, Ann Rheum Dis, 2018.

F. Cantini and M. Benucci, Response to: 'Seeing the glass either half full or half empty: response to the correspondence 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?'' by Scherlinger and Schaeverbeke, Ann Rheum Dis, 2018.

M. Scherlinger and T. Schaeverbeke, Additional response to the correspondence: 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Cantini and Bennuci, Ann Rheum Dis, 2018.

D. Dgos and D. , août 2017 relative aux médicaments biologiques, à leurs similaires ou « biosimilaires, 2017.

J. Kay, M. M. Schoels, T. Dörner, P. Emery, T. K. Kvien et al., Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases, Ann Rheum Dis, vol.77, pp.165-74, 2018.

A. Sarradon, M. Blanc, and M. Faure, Des usagers sceptiques face aux médicaments génériques : une approche anthropologique, Epidemiol Public Health Rev Epidémiologie Santé Publique, vol.55, pp.179-85, 2007.

M. Scherlinger, E. Langlois, and V. Germain, Acceptance Rate And Sociological Factors Involved In The Switch From Originator To Biosimilar Etanercept (SB4). Semin Arthritis Rheum, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01992911

L. Tweehuysen, B. Van-den-bemt, I. L. Van-ingen, A. De-jong, W. H. Van-der-laan et al., Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab, Arthritis Rheumatol, vol.70, pp.60-68, 2018.

M. Scherlinger, V. Germain, C. Labadie, T. Barnetche, M. Truchetet et al., Switching from originator infliximab to biosimilar CT-P13 in real-life: the weight of patient acceptance, Joint Bone Spine, 2017.

W. Park, D. H. Yoo, P. Miranda, M. Brzosko, P. Wiland et al., Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study, Ann Rheum Dis, 2016.

D. H. Yoo, N. Prodanovic, J. Jaworski, P. Miranda, E. Ramiterre et al., Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study, Ann Rheum Dis, 2016.

M. F. Rezk and B. Pieper, Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect, Rheumatol Ther, vol.4, pp.209-227, 2017.

S. Mouly, J. Bergmann, and M. Molimard, L'effet Nocebo : particularités et conséquences pour le clinicien, Rev Médecine Interne, vol.39, pp.315-335, 2018.

. Ims, The Impact of Biosimilar Competition in Europe, 2017.

, INSTRUCTION N° DSS/1C/DGOS/PF2/2018/42 du 19 février 2018 relative à l'incitation à la prescription hospitalière de médicaments biologiques similaires, lorsqu'ils sont délivrés en ville n, 2018.

. Iv and . Références,

E. Minichiello, L. Semerano, M. Boissier, and . Incidence, prévalence et sévérité de la polyarthrite rhumatoïde au XXI e siècle, vol.84, pp.303-313, 2017.

A. Rat, Épidémiologie de la spondyloarthrite au xxie siècle, Rev Rhum Monogr, vol.81, pp.225-234, 2014.

S. Dadoun, N. Zeboulon-ktorza, C. Combescure, M. Elhai, S. Rozenberg et al., Mortality in rheumatoid arthritis over the last fifty years: Systematic review and meta-analysis, Joint Bone Spine, vol.80, pp.29-33, 2013.

P. Poppelaars, L. Tuyl, . Van, and M. Boers, OP0015 Mortality of the cobra early rheumatoid arthritis trial cohort after 23 years follow up, Ann Rheum Dis, vol.77, pp.57-57, 2018.

B. Vezér, Z. Buzás, M. Sebeszta, and Z. Zrubka, Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents, Curr Med Res Opin, vol.32, pp.829-863, 2016.

, European Medicines Agency -Multidisciplinary -Similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical issues n, 2018.

L. Gulácsi, V. Brodszky, P. Baji, H. Kim, S. Y. Kim et al., Biosimilars for the management of rheumatoid arthritis: economic considerations, Expert Rev Clin Immunol, vol.11, pp.43-52, 2015.

M. I. Aladul, R. W. Fitzpatrick, and S. R. Chapman, Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK, BioDrugs Clin Immunother Biopharm Gene Ther, vol.31, pp.533-577, 2017.

L. Tweehuysen, B. Van-den-bemt, I. L. Van-ingen, A. De-jong, W. H. Van-der-laan et al., Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab, Arthritis Rheumatol, vol.70, pp.60-68, 2018.

J. Avouac, A. Moltó, V. Abitbol, A. Etcheto, A. Salcion et al., Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Semin Arthritis Rheum, vol.47, pp.741-749, 2018.

M. F. Rezk and B. Pieper, Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect, Rheumatol Ther, vol.4, pp.209-227, 2017.

K. K. Jørgensen, I. C. Olsen, G. L. Goll, M. Lorentzen, N. Bolstad et al., Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial, The Lancet, vol.389, issue.17, pp.30068-30073, 2017.

B. Glintborg, I. J. Sørensen, A. G. Loft, H. Lindegaard, A. Linauskas et al., A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry, Ann Rheum Dis, vol.76, pp.1426-1457, 2017.

H. P. Cohen, A. Blauvelt, R. M. Rifkin, S. Danese, S. B. Gokhale et al., Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes, Drugs, vol.78, pp.463-78, 2018.

. Ims, The Impact of Biosimilar Competition in Europe, 2017.

, INSTRUCTION N° DSS/1C/DGOS/PF2/2018/42 du 19 février 2018 relative à l'incitation à la prescription hospitalière de médicaments biologiques similaires, lorsqu'ils sont délivrés en ville n, 2018.

C. Jacomet, C. Allavena, F. Peyrol, B. Pereira, L. M. Joubert et al., Perception of antiretroviral generic medicines: one-day survey of HIV-infected patients and their physicians in France, PloS One, vol.10, p.117214, 2015.

J. J. Van-netten, A. Francis, A. Morphet, L. V. Fortington, K. Postema et al., Communication techniques for improved acceptance and adherence with therapeutic footwear, Prosthet Orthot Int, vol.41, pp.201-205, 2017.

L. Pouillon, M. Socha, B. Demore, N. Thilly, V. Abitbol et al., The nocebo effect: a clinical challenge in the era of biosimilars, Expert Rev Clin Immunol, vol.2018, pp.1-11

, Les médicaments biosimilaires : données de la Nouvelle-Aquitaine, journée régionale de l'OMEDIT Nouvelle-Aquitaine juin 2017